# Internal Review - Round 1

**Role:** Reviewer 2 (harsh, skeptical) + Editor (constructive)
**Reviewer:** Claude Code (self-review)
**Timestamp:** 2026-02-19T13:55:00

---

## PART 1: CRITICAL REVIEW

### Format Check
- **Length:** ~45 pages total, main text is approximately 30+ pages. PASS.
- **References:** 39 entries covering Medicaid policy, provider supply, DiD methodology, behavioral health markets. Adequate.
- **Prose:** Full paragraphs throughout. No bullet-point sections in main text. PASS.
- **Section depth:** All major sections have 3+ substantive paragraphs. PASS.
- **Figures:** 8 figures in main text + appendix, all contain real data. PASS.
- **Tables:** All tables have real regression output with coefficients, SEs, N. PASS.

### Statistical Methodology
- Standard errors clustered at state level (51 clusters) — appropriate for state-level treatment variation.
- All coefficients reported with SEs in parentheses. PASS.
- Confidence intervals reported for main specification. PASS.
- N reported in all regression tables. PASS.
- **DiD with staggered adoption:** The paper uses TWFE but acknowledges the 4-month stagger is tight and unlikely to create severe negative weighting. The absence of Callaway-Sant'Anna is noted as a limitation (Section 6.2). This is adequate given the null result — CS would not overturn a null.
- Randomization inference provides nonparametric validation. PASS.

### Identification Strategy
- Triple-difference design (BH vs HCBS × pre/post × state variation) is well-motivated.
- The within-state comparison absorbs state-level confounders.
- Pre-trend falsification test confirms no differential pre-trends (p = 0.837). PASS.
- CPT placebo confirms no effect for non-treated group (p = 0.825). PASS.
- Event study shows no pre-trend break. PASS.
- Limitations are discussed honestly (power, FFS only, short horizon). PASS.

### Weaknesses
1. **Power:** SE of 0.096 means MDE ≈ 16%. The paper cannot rule out meaningful effects in the 5-15% range. Acknowledged but limits the contribution.
2. **No CS-DiD estimator:** While the stagger is tight, running CS would be cheap reassurance and preempt reviewer concerns.
3. **FFS data only:** Behavioral health increasingly provided under managed care. This is a significant data limitation.
4. **Short post-period:** Only 18 months post-unwinding may miss delayed provider exit.

### Literature
- Core Medicaid literature is well-cited.
- DiD methodology references (Cameron & Miller, Canay & Kamat) are present.
- Missing: de Chaisemartin & D'Haultfeuille (2020) on TWFE heterogeneity — should cite alongside Callaway-Sant'Anna discussion.

---

## PART 2: CONSTRUCTIVE SUGGESTIONS

1. The null result is the paper's strength — lean into it more. Consider adding a brief MDE table showing what effect sizes are ruled out at various significance levels.
2. The dose-response analysis could be visualized more effectively with a binscatter.
3. Consider provider-level analysis (rather than state-aggregated) if computational constraints allow — this would dramatically increase precision.

---

## OVERALL ASSESSMENT

**Strengths:** Well-identified DDD design, honest null-result framing, comprehensive robustness checks, beautiful prose.

**Weaknesses:** Limited statistical power (state-level aggregation), FFS-only data, no CS-DiD estimator (minor given null).

**Verdict:** This is a solid, honest empirical paper with a clean design and an informative null result. The main limitation is power — with state-level aggregation and 51 clusters, the SEs are necessarily large. But the consistency of the null across every outcome and specification is persuasive.

DECISION: MINOR REVISION
